Open Access
ARTICLE
Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience
Stefania Nobili*, Daniele Lavacchi†, Gabriele Perrone*, Giulio Vicini†, Renato Tassi‡1, Ida Landini*,
AnnaMaria Grosso§, Giandomenico Roviello*¶, Roberto Mazzanti‡, Carmine Santomaggio¶2, Enrico Mini*¶
* Section of Clinical Pharmacology and Oncology, Department of Health Science, University of Florence, Florence, Italy
† School of Human Health, University of Florence, Florence, Italy
‡ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
§ Unit of Pneumology and Thoracic-Pulmonary Physiopathology, Careggi University Hospital, Florence, Italy
¶ Unit of Translational Oncology, Careggi University Hospital, Florence, Italy
Oncology Research 2020, 28(3), 237-248. https://doi.org/10.3727/096504019X15755437099308
Abstract
The use of vinorelbine as a single agent or in combination regimens in non-small cell lung cancer (NSCLC) is
associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectable or metastatic NSCLC patients, according to real-world treatment patterns, has
still not been widely explored. Eighty-one patients treated at a single institution were retrospectively analyzed.
Thirty-seven received standard first-line single-agent vinorelbine, and 44 received vinorelbine plus platinum
drugs, based on physician’s choice; 61.7% were older than 70 years, and 60.5% were affected by 2 comorbidities. Sixty-three patients were evaluable for objective response: 22% achieved partial response and 41% stable
disease. Median progression-free survival (PFS) was 5.4 months. A benefit in PFS was observed in patients
treated with combinations vs. single-agent vinorelbine (6.7 vs. 3.5 months,
p=0.043). Median overall survival
(OS) was 10.4 months without a statistically significant difference between treatments (12.4 vs. 7.5 months).
In 55 stage IV patients, OS was positively correlated with combination regimens, M1a stage, or 2 metastatic
lesions. Grade 3–4 toxicity occurred in 33% of patients, and dose reduction in 11%. A statistically significant
higher incidence of toxicity was observed in patients receiving combinations, in women, in patients younger
than 75 years, or patients with metastases. In this real-word analysis, we confirmed the efficacy and tolerability
of vinorelbine as a single agent or combined with platinums in patients usually underrepresented in controlled
clinical trials. Single-agent vinorelbine may represent a suitable option in elderly or unfit NSCLC patients and
warrants investigation as a potential drug candidate for immunochemotherapy combination regimens.
Keywords
Cite This Article
Nobili, S., Lavacchi, D., Perrone, G., Vicini, G., Tassi, R. et al. (2020). Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience.
Oncology Research, 28(3), 237–248.